An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo

European Journal of Dermatology

Volumn 19, Issue 6, 2009, Pages 588-593

  Stinco, Giuseppe ^a   Piccirillo, Fabio ^a   Forcione, Marina ^a   Valent, Francesca ^a   Patrone, Pasquale ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Narrow band ultraviolet B; Pimecrolimus; Tacrolimus; Vitiligo

Indexed keywords

PIMECROLIMUS; SUNSCREEN; TACROLIMUS;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EPIPHORA; ERYTHEMA; FEMALE; FLUSHING; FORMICATION; HEAT SENSATION; HUMAN; MALE; MEDICAL PHOTOGRAPHY; PHOTOTHERAPY; PRURITUS; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DEFECT; SKIN IRRITATION; SKIN PAIN; SKIN PIGMENTATION; SKIN PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO;

EID: 73249119523     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0779     Document Type: Article

References (26)

1. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148: 1219-28.
2. Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407-16.
3. Firooz A, Bouzari N, Fallah N, et al. What patients with vitiligo believe about their condition. Int J Dermatol 2004; 43: 811-4.
4. Kent G, Al'Abadie M. Psychological effects of vitiligo : a critical incident analysis. J Am Acad Dermatol 1996; 35: 595-8.
5. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44: 999-1003.
6. Gambichler T, Breuckmann F, Boms S, et al. Narrow-band UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 2005; 52: 660-70.
7. Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrowband ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175-7.
8. De Francesco V, Stinco G, Laspina S, et al. Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo. Eur J Dermatol 2008; 18: 292-6.
9. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
10. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62.
11. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs. 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
12. Seirafi H, Farnaghi F, Firooz A, et al. Pimecrolimus cream in repigmentation of vitiligo. Dermatology 2007; 214: 253-9.
13. Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007; 17: 55-61.
14. Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin Pharmacother 2006; 7: 1967-75.
15. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133: 1525-8.
16. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-53.
17. Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol 2007; 21: 891-6.
18. Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol 2005; 44: 57-60.
19. Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005; 30: 332-6.
20. Dawid M, Veensalu M, Grassberger M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled styudy. J Dtsch Dermatol Ges 2006; 4: 942-6.
21. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
22. Sardana K, Bhushan P, Kumar GV. Effect of tacrolimus on vitiligo in absence of UV radiation exposure. Arch Dermatol 2007; 143: 119-20.
23. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.
24. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
25. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5.
26. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a rewiew of 57 cases. J Am Acad Dermatol 2004; 51: 760-6.